CY1108700T1 - Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης - Google Patents

Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης

Info

Publication number
CY1108700T1
CY1108700T1 CY20091100038T CY091100038T CY1108700T1 CY 1108700 T1 CY1108700 T1 CY 1108700T1 CY 20091100038 T CY20091100038 T CY 20091100038T CY 091100038 T CY091100038 T CY 091100038T CY 1108700 T1 CY1108700 T1 CY 1108700T1
Authority
CY
Cyprus
Prior art keywords
methods
release compositions
acid release
drug
alpha
Prior art date
Application number
CY20091100038T
Other languages
English (en)
Inventor
John M Lipari
Michelle A Long
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1108700T1 publication Critical patent/CY1108700T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Περιγράφονται συνθέσεις απελευθέρωσης που έχουν άλφα-υδρόξυ οξέος εστέρα και ακυλγλυκερίνη ως τμήμα μιας σύνθεσης φορέα για φαρμακευτικά δραστικά φάρμακα ή προφάρμακα. Αυτές οι φαρμακοτεχνικές μορφές εμφανίζουν μοναδικές ιδιότητες που στοχεύουν στην απελευθέρωση φαρμάκου σε ένα υποκείμενο.
CY20091100038T 2003-03-31 2009-01-14 Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης CY1108700T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/403,071 US20040191207A1 (en) 2003-03-31 2003-03-31 Alpha-hydroxy acid ester drug delivery compositions and methods of use
EP04759681A EP1608346B1 (en) 2003-03-31 2004-03-19 Alpha-hydroxy acid ester drug delivery compositions and methods of use

Publications (1)

Publication Number Publication Date
CY1108700T1 true CY1108700T1 (el) 2014-04-09

Family

ID=32989847

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100038T CY1108700T1 (el) 2003-03-31 2009-01-14 Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης

Country Status (14)

Country Link
US (1) US20040191207A1 (el)
EP (1) EP1608346B1 (el)
JP (2) JP5005339B2 (el)
AT (1) ATE413865T1 (el)
CA (1) CA2518918C (el)
CY (1) CY1108700T1 (el)
DE (1) DE602004017705D1 (el)
DK (1) DK1608346T3 (el)
ES (1) ES2317017T3 (el)
MX (1) MXPA05010607A (el)
PL (1) PL1608346T3 (el)
PT (1) PT1608346E (el)
SI (1) SI1608346T1 (el)
WO (1) WO2004093851A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238672A1 (en) * 2004-04-27 2005-10-27 Nimni Marcel E Antifungal drug delivery
DE102010013064A1 (de) 2010-03-26 2011-12-15 Gabriele Blume Neuartiges Trägersystem für den Transport von Wirkstoffen in die Haut
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
IL274893B1 (en) 2017-11-27 2024-04-01 Umecrine Cognition Ab Pharmaceutical formulation of 3 alpha-ethynyl-3 beta-hydroxyandrostan-17-one oxime
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492325A (en) * 1967-03-24 1970-01-27 Procter & Gamble Production of alpha-hydroxy acids and esters
US5002771A (en) * 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
CZ278863B6 (en) * 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JPH1081621A (ja) * 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
CA2185600A1 (en) * 1996-09-16 1998-03-17 Bernard Charles Sherman Water-soluble concentrates containing cyclosporins
GB9621990D0 (en) * 1996-10-22 1996-12-18 Scotia Pharma Ltd Use
JP2000514100A (ja) * 1997-07-01 2000-10-24 ファイザー・プロダクツ・インク 可溶化されたセルトラリン組成物
CA2313024C (en) * 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
BR0010354A (pt) * 1999-05-07 2002-03-05 Pharmasol Gmbh Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção
WO2000074652A1 (de) * 1999-06-02 2000-12-14 Hexal Ag Pharmazeutische zusammensetzung zur nasalen anwendung von wasserlöslichen wirkstoffen
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE19943678A1 (de) * 1999-09-13 2001-03-15 Beiersdorf Ag Wirkstoffkombinationen aus oberflächenaktiven Citronensäureestern und Einschlußverbindungen von Cyclodextrinen und Retinoiden sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations

Also Published As

Publication number Publication date
CA2518918C (en) 2011-08-09
EP1608346B1 (en) 2008-11-12
JP5592905B2 (ja) 2014-09-17
DK1608346T3 (da) 2009-01-26
DE602004017705D1 (de) 2008-12-24
ES2317017T3 (es) 2009-04-16
JP2012136521A (ja) 2012-07-19
MXPA05010607A (es) 2005-11-23
EP1608346A1 (en) 2005-12-28
SI1608346T1 (sl) 2009-04-30
JP2006522105A (ja) 2006-09-28
JP5005339B2 (ja) 2012-08-22
ATE413865T1 (de) 2008-11-15
PL1608346T3 (pl) 2009-07-31
WO2004093851A1 (en) 2004-11-04
US20040191207A1 (en) 2004-09-30
PT1608346E (pt) 2009-02-06
CA2518918A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
RS51764B (en) TRANSDERMAL PHARMACEUTICAL COMPOSITION
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
MEP18208A (en) Immune response modifier foam formulations
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
PH12012500765A1 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
BRPI0515316A (pt) compostos de imidazoquinolina
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
AR050717A1 (es) Composiciones farmaceuticas
CR9587A (es) Derivados de piridazina
ES2572157T3 (es) Composiciones en forma de partículas para la administración de fármacos poco solubles
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
CR9703A (es) Derivados de pirazolona
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
MX2010005714A (es) Compuestos de piridina.
DE602006000819D1 (de) Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung
MX2007006775A (es) Composiciones estables de fenofibrato con esteres de acido graso.
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.